pyrazines has been researched along with Lymphoproliferative Disorders in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P | 1 |
| Aguilar-Company, J; Los-Arcos, I; Ruiz-Camps, I | 1 |
| Fancher, KM; Pappacena, JJ | 1 |
| Aksenov, S; Al-Huniti, N; Andrew, MA; Edlund, H; Lee, SK; Slatter, JG | 1 |
| Farmer, DG; Kempert, P; Plant, AS; Said, J; Upadhyay, S; Venick, RS | 1 |
| Dondero, R; Francis, SM; Liu, Z; Tang, T; Taylor, CA; Thompson, JE; Zheng, Q | 1 |
| Baz, RC; Bose, P; Colevas, AD; Coppola, D; Dawson, J; Doyle, LA; Figg, WD; Grant, S; Hogan, KT; Holkova, B; Honeycutt, C; Kang, L; Kmieciak, M; Peer, CJ; Perkins, EB; Ramakrishnan, V; Roberts, JD; Roodman, GD; Sankala, H; Shrader, E; Stuart, RK; Sullivan, D; Tombes, MB; Wan, W; Weir-Wiggins, C; Wellons, M | 1 |
| Agathocleous, A; Hunter, H; Johnson, P; Kerr, JP; Lister, A; Matthews, J; Montoto, S; Neeson, SM; Radford, J; Rohatiner, A; Rule, S; Strauss, S | 1 |
| Ewald, GA; Hassan, A; Joseph, SM; Klein, JL; Uy, GL; Wang, TF; Woodard, PK | 1 |
| Carbone, R; Lacy, J; Loomis, R; Srimatkandada, P; Srimatkandada, S | 1 |
1 review(s) available for pyrazines and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Communicable Disease Control; Humans; Immune Checkpoint Inhibitors; Infections; Lymphoproliferative Disorders; Piperidines; Purines; Pyrazines; Quinazolinones; Risk; Rituximab; Sulfonamides; Syndrome | 2020 |
3 trial(s) available for pyrazines and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
Topics: Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Healthy Volunteers; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Pyrazines; Young Adult | 2019 |
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Drug Monitoring; Female; Flavonoids; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Pyrazines; Recurrence; Retreatment; Treatment Outcome | 2014 |
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Pyrazines; Rituximab; Survival Analysis; Treatment Outcome; Waldenstrom Macroglobulinemia | 2010 |
6 other study(ies) available for pyrazines and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunocompromised Host; Infections; Lymphopenia; Lymphoproliferative Disorders; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazines; Quinazolinones; Retrospective Studies; Risk Factors; Sulfonamides; Young Adult | 2021 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbidity; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inducers; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Food-Drug Interactions; Fruit and Vegetable Juices; Hematologic Neoplasms; Humans; Lymphoproliferative Disorders; Piperidines; Polypharmacy; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction | 2020 |
Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Dexamethasone; Female; Humans; Immunocompromised Host; Infant; Intestine, Small; Liver Transplantation; Lymphoproliferative Disorders; Pyrazines | 2013 |
SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Translation Initiation Factor 5A; Humans; Lenalidomide; Lymphoproliferative Disorders; Mice; Nanoparticles; Neoplasm Transplantation; Peptide Initiation Factors; Polyethyleneimine; Pyrazines; RNA-Binding Proteins; RNA, Small Interfering; Thalidomide; Xenograft Model Antitumor Assays | 2014 |
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Neoplasms; Heart Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lymphoproliferative Disorders; Plasmacytoma; Pyrazines | 2012 |
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Caspases; Cell Line, Transformed; Cell Proliferation; Enzyme Activation; Herpesvirus 4, Human; Humans; Lymphocytes; Lymphoproliferative Disorders; Nitriles; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines | 2008 |